Pantarhei Oncology BV (PRO) is a bio-pharmaceutical company located in the Netherlands with an innovative approach towards drug development in cancers sensitive for endocrine treatment or immunotherapy.
PRO is a subsidiary company of Pantarhei Bioscience BV.
Based upon thorough scientific knowledge and divergent thinking, we discover new treatments for Reproductive Endocrine Oncology using our endocrine scientific healthcare background. Our goal is to develop effective treatments that improve patients’ wellbeing.
The company has developed a sustainable product pipeline based on its ability to identify novel medical uses of targets, hormones, biologicals, drugs or combinations thereof in these areas of medicine. The main area of expertise of PRO is Reproductive Endocrine Oncology, including breast cancer, prostate cancer and ovarian cancer.
The business model of PRO is based on creating intellectual property (IP) of new treatment concepts and providing in-house project management. All research and development activities are outsourced. PRO develops patent protected treatments up to phase II efficacy and safety. Using existing molecules often provides first evidence of safety. After generating favourable and safe human proof-of-concept data, projects are sold or licensed-out to a (pharmaceutical) partner for final development (phase III), regulatory approval and commercialisation. Over the years, Pantarhei has sold and licensed a series of unique treatment concepts.
For more information, see Corporate story.